Discover the breakthrough medications set to dominate 2025. Explore treatments, key innovations, and market trends shaping the future of pharma.
Which new market entrants should be on the industry’s radar in 2025? What new products, recently launched or expected to launch in 2025, show blockbuster potential? We take a look at the leading contenders.
Each year, the pharmaceutical industry anticipates the launch of new therapeutics with significant commercial potential. According to the 2025 “Drugs to Watch” report by Clarivate, 10 new drugs are projected to achieve blockbuster status (defined as $1 billion or more in annual sales) by 2030. These drugs, either newly launched or in late-stage trials, have the potential to transform treatment paradigms in their respective fields. Below, we highlight 10 of these high-impact drugs poised to shape the industry landscape in 2025.
1. Moderna’s mRESVIA – A Key Player in the RSV Vaccine Market
Following the success of COVID-19 mRNA vaccines, Moderna’s mRESVIA is set to compete in the respiratory syncytial virus (RSV) vaccine market alongside GSK and Pfizer’s recently launched vaccines. Moderna’s mRNA platform could provide a unique edge, and the vaccine’s success in older adults and high-risk populations will be crucial in determining its commercial trajectory.
2. Sanofi and Alnylam’s Fitusiran – A Breakthrough for Hemophilia A and B
Fitusiran, an RNA interference (RNAi) therapeutic, reduces antithrombin levels to promote thrombin generation, helping hemophilia patients achieve better clotting balance. Expected to secure FDA approval by March 2025, this novel approach could make Fitusiran the first-of-its-kind RNA-based hemophilia therapy. Clarivate projects sales of $1 billion by 2030, reflecting its strong potential in the rare disease space.
3. Novo Nordisk’s CagriSema (Cagrilintide and Semaglutide) – A Dual-Action Obesity and Diabetes Treatment
CagriSema combines the proven benefits of semaglutide (found in Ozempic and Wegovy) with cagrilintide, an amylin analog that enhances glucose regulation and appetite control. Expected to become the first fixed-dose combination of amylin and GLP-1 receptor agonists, the drug has a projected market of $4.7 billion for obesity and $3.6 billion for Type 2 diabetes by 2030, positioning it as a strong competitor to existing GLP-1 therapies.
4. Novo Nordisk’s Awiqli (Basal Insulin Icodec) – A Once-Weekly Insulin Revolution
Awiqli is the first once-weekly subcutaneous insulin for Type 1 and Type 2 diabetes, offering a major shift from daily basal insulin regimens. The drug is already approved in several global markets but is awaiting FDA approval in the U.S. after regulatory delays in 2024. With projected 2030 sales of $4.7 billion in key global markets, Awiqli has the potential to redefine long-term insulin therapy, particularly in Type 2 diabetes, where patient adherence is a critical factor.
5. Pfizer and Arvinas’ Vepdegestrant – A Next-Generation Breast Cancer Therapy
Vepdegestrant, an investigational selective estrogen receptor degrader (SERD), targets ER+/HER2- breast cancer, addressing a large unmet need for patients resistant to current endocrine therapies. The drug is expected to challenge existing treatments, particularly AstraZeneca’s Faslodex. With promising efficacy and tolerability, Vepdegestrant is positioned for strong commercial uptake post-approval.
6. Eli Lilly and Amirall’s Ebglyss (Lebrikizumab) – A New Standard in Atopic Dermatitis Treatment
As the third biologic targeting the IL-13 pathway for eczema, Ebglyss differentiates itself with a more selective inhibition profile and less frequent dosing compared to competitors like Dupixent (Sanofi) and Adtralza (Leo Pharma). With projected 2030 sales of $6 billion, Ebglyss is expected to establish itself as a leading first-line treatment for moderate-to-severe atopic dermatitis.
7. GSK’s Neisseria Meningitidis (A, B, C, W, and Y) Vaccine (GSK-3536819) – A Broad-Spectrum Meningitis Vaccine
GSK’s five-in-one vaccine candidate aims to protect against all major Neisseria meningitidis serogroups responsible for invasive meningococcal disease. This comprehensive protection makes it a significant advancement over existing meningitis vaccines. With broad global applicability and high demand for enhanced meningococcal coverage, GSK-3536819 is expected to generate blockbuster sales by 2030.
8. Exelixis’ Zanzalintinib – A Targeted Therapy for Chronic Gout
Zanzalintinib, a novel small-molecule inhibitor, is being developed for chronic gout treatment, offering an alternative to urate-lowering therapies. With an increasing prevalence of gout due to dietary and lifestyle factors, the drug has strong commercial potential if it demonstrates superior efficacy and safety in late-stage trials.
9. Amgen’s Imdelltra (Tarlatamab-dlle) – A New Hope for Small-Cell Lung Cancer
Imdelltra is a first-in-class delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE) for extensive-stage small-cell lung cancer (SCLC). The drug showed promising Phase II results and could fill a critical treatment gap in a cancer type with limited therapeutic options. Given the high mortality rate of SCLC, Imdelltra is expected to drive strong adoption post-launch.
10. Bristol-Myers Squibb’s Cobenfy (Xanomeline-Trospium) – A Novel Approach for Schizophrenia
Approved by the FDA in September 2024 for schizophrenia, Cobenfy represents a departure from traditional dopamine-targeting antipsychotics. Instead, it acts on cholinergic receptors, potentially reducing common side effects associated with dopamine modulation. With an additional indication in Alzheimer’s-related psychosis under evaluation, Cobenfy’s projected 2030 sales stand at $1.6 billion, signaling strong commercial promise.
The Outlook for 2025 and Beyond
The pharmaceutical landscape in 2025 is set to be shaped by a mix of first-in-class therapies, novel combination treatments, and innovative vaccines. These drugs, spanning metabolic disorders, oncology, neurology, immunology, and rare diseases, highlight the industry’s shift toward targeted, high-value treatments. As these contenders move through regulatory pathways and into commercialization, their impact on patient care and market dynamics will be closely watched.
With sales projections in the billions and the potential to redefine standard-of-care treatments, these 10 drugs represent the cutting edge of pharmaceutical innovation for 2025 and beyond.
Breakthrough Medications
Breakthrough Medications
Comments are closed.
